Is Selling Stock Like Valeant Pharmaceuticals Intl Inc After Such Decline Winning Strategy?

 Is Selling Stock Like Valeant Pharmaceuticals Intl Inc After Such Decline Winning Strategy?

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 385,553 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 67.01% since March 10, 2016 and is downtrending. It has underperformed by 72.63% the S&P500.
The move comes after 9 months negative chart setup for the $9.49 billion company. It was reported on Oct, 17 by Barchart.com. We have $27.27 PT which if reached, will make TSE:VRX worth $474.50M less.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 2 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $74 is the highest target while $38 is the lowest. The $42.75 average target is 48.95% above today’s ($28.7) stock price. Valeant Pharmaceuticals International has been the topic of 12 analyst reports since October 20, 2015 according to StockzIntelligence Inc. As per Tuesday, May 24, the company rating was maintained by RBC Capital Markets. The rating was maintained by TD Securities with “Hold” on Wednesday, July 20. TD Securities maintained the shares of VRX in a report on Thursday, August 11 with “Buy” rating. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (TSE:VRX) rating on Tuesday, October 11. RBC Capital Markets has “Sector Perform” rating and $47.50 price target. The firm has “Sector Perform” rating given on Tuesday, September 20 by RBC Capital Markets. The stock has “Outperform” rating given by RBC Capital Markets on Tuesday, January 26. The company was maintained on Friday, June 3 by RBC Capital Markets. The firm earned “Sector Perform” rating on Wednesday, September 7 by RBC Capital Markets. RBC Capital Markets maintained the shares of VRX in a report on Monday, June 27 with “Sector Perform” rating. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, June 20.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “These 2 Factors Pushed Valeant Pharmaceuticals Intl. Inc. Down 15% in September” on October 07, 2016, also Fool.com with their article: “Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc” published on September 30, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock to Regain Value?” on September 27, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Investorplace.com and their article: “2 Ways to Make Bank on Valeant Pharmaceuticals Intl Inc (VRX)” published on October 10, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Stock: Many Are Bullish on Valeant Pharmaceuticals Intl Inc” with publication date: September 18, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $9.49 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment